

Mutational landscape and expression of PD-L1 in patients with NSCLC harboring genomic alterations of MET

*Alessa Fischer*¹, *Lorenz Bankel*¹, *Stefanie Hiltbrunner*¹, *Markus Rechsteiner*², *Jan H. Rüschhoff*², *Elisabeth Jane Rushing*², *Christian Britschgi*¹, *Alessandra Curioni-Fontecedro*^{1,*}

¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland

² Institute of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland

* Corresponding author: PD Dr. med. Alessandra Curioni-Fontecedro, alessandra.curioni@usz.ch, +41 44 255 22 14

E-mail address of authors:

Alessa Fischer: alessac.fischer@gmail.com

Lorenz Bankel: lorenz.bankel@usz.ch

Stefanie Hiltbrunner: stefanie.hiltbrunner@usz.ch

Markus Rechsteiner: markus.rechsteiner@usz.ch

Jan Rüschhoff: janhendrik.rueschoff@usz.ch

Elisabeth Rushing: ElisabethJane.Rushing@usz.ch

Christian Britschgi: christian.britschgi@usz.ch

Running Heading: Mutational landscape and PD-L1 expression in NSCLC harboring genomic *MET* alterations

Electronic Supplementary Material

Supplementary Table 1

Genes with co-mutations of unknown significance in MET exon 14-altered, MET amplified and MET overexpressing tumors.

Patient Nr	Co-mutations
1	AXIN1, BRD4, GSK3B, SDHA, TET2
2	ABL1, BAP1, FGFR3, MAP2K2, MTOR, TNFAIP3, ZNF703
9	CBL, KDM6A, MAP3K1, SPEN, WHSC1
10	PALB2, SDHA, SNCAIP
16	ALK, CEBPA, ERBB3, FLT1, MSH3, NTRK3, PARK2, PDGFRB
18	BCL6, BCORL1, DOT1L, FLT1, GABRA6, LTK, MED12, NTRK2, NTRK3, ROS1
24	FGF12, GRM3, PDGFR, RET, SDHA
25	DNMT3A, HSD3B1, LYN, MAP3K1, POLE, SMO
27	AXL, BRAF, BRCA2, DNMT3A, EP300, ERFF11, FANCA, IKBKE, IKZF1, KDMC5, KIT, KRAS, NF1, PDGFRA, PTEN, SDHA, SETD2, SMAD2, TBX3
29	AKT2, CARD11, CBL, CSF3R, FGF10, GNAS, GRM3, MLL2, NF1, PARP3, ZNF217
30	ARFRP1, ARTX, BARD1, BRIP1, CHEK1, ERCC4, FANCA, MEF2B, MERTK,
36	ATM, CEBPA, C11orf30, DDR1, FLT1, KEAP1, PTPRO, RNF43, STK11, TEK,
39	MLL, NSD3, PTRO
66	ALOX12B, APC, NKX3-1, BRCA1, NTRK1, DOTL1
81	KEAP1, PARP2, SRC, PDGFRa/b, STK11
89	CDKN2B, KEAP, LRP18, MTF, ROS1, SMARCA4




Figure S1




Figure S2